Caribou Biosciences Share Price (NASDAQ: CRBU)

$1.86

▲

-0.08

(-4.12%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Caribou Biosciences Stock chart to analyse performance

Caribou Biosciences stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$1.84
Today's High:$1.93
$1.86
1.08%
Downside
Day's Volatility :4.66%
Upside
3.63%
52 Weeks Low:$0.66
52 Weeks High:$3.00
$1.86
64.52%
Downside
52 Weeks Volatility :78.0%
Upside
37.99%

Caribou Biosciences Stock Returns

Period	Caribou Biosciences	Sector (Health Care)	Index (Russel 2000)
3 Months	91.3%	3.6%	0.0%
6 Months	74.3%	-7.7%	0.0%
1 Year	-5.81%	-12.6%	0.0%
3 Years	-82.27%	9.5%	-4.7%

Caribou Biosciences Key Stats

Check Caribou Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.94
Open	$1.93
Today's High	$1.93
Today's Low	$1.84
Market Capitalization	$180.7M
Today's Volume	$486.5K
52 Week High	$2.9995
52 Week Low	$0.66
Revenue TTM	$9.1M
EBITDA	$-146.3M
Earnings Per Share (EPS)	$-1.78
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-68.93%

Stock Returns calculator for Caribou Biosciences Stock including INR - Dollar returns

The Caribou Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Caribou Biosciences investment value today

Current value as on today

₹91,395

Returns

₹8,605

(-8.6%)

Returns from Caribou Biosciences Stock

₹13,889 (-13.89%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Caribou Biosciences Stock

-26%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Caribou Biosciences Stock from India on INDmoney has decreased by -26% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Caribou Biosciences

Name
Holdings %
Name
Holdings %
BlackRock Inc
6.82%
Pfizer Inc
5.04%
Vanguard Group Inc
4.39%
Kynam Capital Management, LP
3.29%
Schonfeld Strategic Advisors LLC
2.44%
Geode Capital Management, LLC
2.21%

Analyst Recommendation on Caribou Biosciences Stock

Rating

Trend

Buy

86%Buy

13%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Caribou Biosciences(by analysts ranked 0 to 5 stars)

Caribou Biosciences Share Price Target

What analysts predicted

Upside of 376.19%

Target:

$8.86

Current:

$1.86

Caribou Biosciences share price target is $8.86, a slight Upside of 376.19% compared to current price of $1.86 as per analysts' prediction.

Caribou Biosciences Stock Insights

Price Movement
In the last 3 months, CRBU stock has moved up by 75.9%
Increasing Revenue
Revenue is up for the last 4 quarters, 2.02M → 2.66M (in $), with an average increase of 8.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -34.68M → -54.09M (in $), with an average decrease of 16.8% per quarter
CRBU vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 83.6%
CRBU vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 193.0%
Price to Sales
ForCRBU every $1 of sales, investors are willing to pay $18.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Caribou Biosciences Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$5.8M	-
Net Income	$-23.4M	-
Net Profit Margin	-404.82%	-

	FY20	Y/Y Change
Revenue	$12.4M	↑ 113.56%
Net Income	$-34.3M	↑ 46.42%
Net Profit Margin	-277.55%	↑ 127.27%

	FY21	Y/Y Change
Revenue	$9.6M	↓ 22.35%
Net Income	$-66.9M	↑ 95.07%
Net Profit Margin	-697.26%	↓ 419.71%

	FY22	Y/Y Change
Revenue	$13.9M	↑ 44.31%
Net Income	$-99.4M	↑ 48.56%
Net Profit Margin	-717.79%	↓ 20.53%

	FY23	Y/Y Change
Revenue	$34.5M	↑ 148.91%
Net Income	$-102.1M	↑ 2.66%
Net Profit Margin	-296.05%	↑ 421.74%

	FY24	Y/Y Change
Revenue	$10.0M	↓ 71.01%
Net Income	$-149.1M	↑ 46.08%
Net Profit Margin	-1.5K%	↓ 1195.9%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$2.4M	↓ 31.73%
Net Income	$-41.2M	↑ 19.5%
Net Profit Margin	-1.7K%	↓ 727.78%

	Q2 FY24	Q/Q Change
Revenue	$3.5M	↑ 42.61%
Net Income	$-37.7M	↓ 8.58%
Net Profit Margin	-1.1K%	↑ 609.32%

	Q3 FY24	Q/Q Change
Revenue	$2.0M	↓ 41.57%
Net Income	$-34.7M	↓ 7.99%
Net Profit Margin	-1.7K%	↓ 625.39%

	Q4 FY24	Q/Q Change
Revenue	$2.1M	↑ 2.62%
Net Income	$-35.5M	↑ 2.32%
Net Profit Margin	-1.7K%	↑ 4.93%

	Q1 FY25	Q/Q Change
Revenue	$2.4M	↑ 13.29%
Net Income	$-40.0M	↑ 12.68%
Net Profit Margin	-1.7K%	↑ 9.13%

	Q2 FY25	Q/Q Change
Revenue	$2.7M	↑ 13.34%
Net Income	$-54.1M	↑ 35.28%
Net Profit Margin	-2.0K%	↓ 328.84%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-17.8M	-

	FY20	Y/Y Change
Profit	$-22.1M	↑ 23.63%

	FY21	Y/Y Change
Profit	$8.6M	↓ 139.04%

	FY22	Y/Y Change
Profit	$10.2M	↑ 18.53%

	FY23	Y/Y Change
Profit	$31.0M	↑ 203.15%

	FY24	Y/Y Change
Profit	$6.1M	↓ 80.4%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.7M	↑ 8.52%

	Q2 FY24	Q/Q Change
Profit	$2.6M	↑ 51.72%

	Q3 FY24	Q/Q Change
Profit	$2.0M	↓ 22.39%

	Q4 FY24	Q/Q Change
Profit	$893.0K	↓ 55.88%

	Q1 FY25	Q/Q Change
Profit	$2.4M	↑ 163.49%

	Q2 FY25	Q/Q Change
Profit	$2.7M	↑ 13.34%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-32.0M	-
Investing Cash Flow	$27.2M	-
Financing Cash Flow	$172.0K	-

	FY20	Y/Y Change
Operating Cash Flow	$-33.2M	↑ 3.78%
Investing Cash Flow	$6.4M	↓ 76.63%
Financing Cash Flow	$1.7M	↑ 908.72%

	FY21	Y/Y Change
Operating Cash Flow	$-32.5M	↓ 2.1%
Investing Cash Flow	$-176.4M	↓ 2872.23%
Financing Cash Flow	$433.4M	↑ 24881.5%

	FY22	Y/Y Change
Operating Cash Flow	$-91.0M	↑ 179.73%
Investing Cash Flow	$-93.2M	↓ 47.14%
Financing Cash Flow	$2.1M	↓ 99.51%

	FY23	Y/Y Change
Operating Cash Flow	$-93.3M	↑ 2.56%
Investing Cash Flow	$-68.2M	↓ 26.88%
Financing Cash Flow	$154.3M	↑ 7133.85%

	FY24	Y/Y Change
Operating Cash Flow	$-138.2M	↑ 48.14%
Investing Cash Flow	$86.6M	↓ 227.02%
Financing Cash Flow	$16.7M	↓ 89.16%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-37.2M	↑ 74.02%
Investing Cash Flow	$23.0M	↓ 172.94%
Financing Cash Flow	$12.5M	↓ 29134.88%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-32.9M	↓ 11.66%
Investing Cash Flow	$21.2M	↓ 7.65%
Financing Cash Flow	$132.0K	↓ 98.94%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-32.7M	↓ 0.62%
Investing Cash Flow	$26.5M	↑ 25.1%
Financing Cash Flow	$244.0K	↑ 84.85%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-35.5M	↑ 8.6%
Investing Cash Flow	$15.9M	↓ 39.93%
Financing Cash Flow	$3.9M	↑ 1483.2%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-36.7M	↑ 3.54%
Investing Cash Flow	$49.4M	↑ 209.99%
Financing Cash Flow	$468.0K	↓ 87.89%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-28.3M	↓ 23.06%
Investing Cash Flow	$24.0M	↓ 51.33%
Financing Cash Flow	$6.0K	↓ 98.72%

Caribou Biosciences Technicals Summary

Sell

Neutral

Buy

Caribou Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Caribou Biosciences Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Caribou Biosciences	-4.36%	74.3%	-5.81%	-82.27%	-88.57%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Caribou Biosciences	NA	NA	NA	-1.64	-0.69	-0.32	NA	1.78
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Caribou Biosciences	Buy	$180.7M	-88.57%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Organization	Caribou Biosciences
Employees	147
CEO	Dr. Rachel E. Haurwitz Ph.D.
Industry	Services

Key Management of Caribou Biosciences

Name	Title
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder, CEO, President & Director
Mr. Timothy P. Kelly M.B.A.	Chief Technology Officer
Ms. Barbara G. McClung Esq., J.D.	Chief Legal Officer & Corporate Secretary
Mr. Sriram Ryali M.B.A.	Chief Financial Officer
Mr. Daniel Poon	Vice President of Operations & Information Technology
Mr. Ryan Fischesser	Interim Principal Accounting Officer & Controller
Ms. Amy Figueroa C.F.A.	Vice President of Investor Relations & Corporate Communications
Ms. Reigin Zawadzki	Chief People Officer
Ms. Ruhi A. Khan M.B.A.	Chief Business Officer
Dr. Tina Albertson M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in CRBU Stock from India :

What is Caribou Biosciences share price today?

Caribou Biosciences share price today is $1.86 as on August 30, 2025 at 1:29 am IST at the close of the market. Caribou Biosciences share today touched a day high of $1.93 and a low of $1.84.

What is the 52 week high and 52 week low for Caribou Biosciences share?

Caribou Biosciences share touched a 52 week high of $3.00 and a 52 week low of $0.66. Caribou Biosciences stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $1.86, lower by 37.99% versus the 52 week high.

How to invest in Caribou Biosciences Stock (CRBU) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Caribou Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Caribou Biosciences Shares that will get you 0.8065 shares as per Caribou Biosciences share price of $1.86 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Caribou Biosciences Stock (CRBU) from India?

Indian investors can start investing in Caribou Biosciences (CRBU) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Caribou Biosciences stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Caribou Biosciences share’s latest price of $1.86 as on August 30, 2025 at 1:29 am IST, you will get 5.3763 shares of Caribou Biosciences. Learn more about fractional shares .

What are the returns that Caribou Biosciences has given to Indian investors in the last 5 years?

Caribou Biosciences stock has given -88.57% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?